Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced the appointment of Dan Monahan as Chief Commercial Officer. Mr. Monahan will also join the Company ...
After raising questions surrounding dosing levels, the FDA has freed Amylyx’s early-stage amyotrophic lateral sclerosis (ALS) ...
Amylyx Pharmaceuticals named Dan Monahan as its chief commercial officer. 1 According to a press release, he is assuming the role in time to oversee the commercialization of avexitide, a GLP-1 ...
Darktrace has announced its first acquisition since its recent takeover by Thoma Bravo in October, as it focuses on ...
Dan Monahan will lead the commercialization strategy across Amylyx’ product portfolio, beginning with avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor ...
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced the appointment of Dan Monahan as Chief Commercial Officer. Mr. Monahan will also join the Company’s Leadership ...
Amylyx (AMLX) Pharmaceuticals announced the appointment of Dan Monahan as Chief Commercial Officer. Mr. Monahan will also join the Company’s Leadership Team. Mr. Monahan joined Amylyx in January ...
Dan Monahan will lead the commercialization strategy across Amylyx’ product portfolio, beginning with avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback